Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 284

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 284
---
 respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027.

Stock options

There were no changes in stock options during the three months ended September 30, 2024.

The following table summarizes stock options outstanding and exercisable under all plans at September 30, 2024:

|                    | Exercise price$ |     | NumberOutstanding atSeptember 30, 2024(in thousands) |     |     | Weightedaverage remainingcontractual life(years) |     |     | Numberexercisable atSeptember 30, 2024(in thousands) |
|:-------------------|:----------------|:----|-----------------------------------------------------:|:----|:----|-------------------------------------------------:|:----|:----|-----------------------------------------------------:|
| 162.93             |                 |     |                                                    2 |     |     |                                             8.92 |     |     |                                                    1 |
| 307.65             |                 |     |                                                    1 |     |     |                                             7.84 |     |     |                                                    1 |
| 1,067.50to1,680.00 |                 |     |                                                    2 |     |     |                                             7.36 |     |     |                                                    2 |
| 2,170.00to2,397.50 |                 |     |                                                    1 |     |     |                                             2.43 |     |     |                                                    — |
|                    |                 |     |                                                    6 |     |     |                                                  |     |     |                                                    4 |

The Company has recognized the following amounts as stock option expense for the periods noted (in thousands):

|                            |     | Three months endedSeptember 30, |    |     |       |     |
|                            |     |                           2024$ |    |     | 2023$ |     |
| Research and development   |     |                                 | 37 |     |       |  69 |
| General and administrative |     |                                 | 61 |     |       |  91 |
|                            |